These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 15639300)

  • 1. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
    Banner KH; Trevethick MA
    Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE4 inhibitors in COPD--a more selective approach to treatment.
    Vignola AM
    Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roflumilast for asthma and chronic obstructive pulmonary disease.
    Cowan C
    Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
    Giembycz MA
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilomilast.
    Schachter EN
    Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 4 inhibitors for the treatment of COPD.
    Sturton G; Fitzgerald M
    Chest; 2002 May; 121(5 Suppl):192S-196S. PubMed ID: 12010850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
    Xia XD; Dai YR; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
    [No Abstract]   [Full Text] [Related]  

  • 16. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
    Tatlicioğlu T
    Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
    Kreutzkamp B
    Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
    Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
    Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.